RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Last trade$4.92
Day change-$0.38 (-7.17%)
Day range$4.90 – $5.92
Volume430,206
Market cap$222M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$222.22M
Price / earnings
—
Price / book
0.87×
Price / sales
1.82×
EV / sales
1.28×
EV / EBITDA
-2.69×
Profitability
Earnings per share
-$1.28
Return on assets
-15.72%
Return on equity
-20.99%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.2×
Quick ratio
3.67×
Cash ratio
0.89×
Cash flow
Price / cash flow
9.39×
Price / free cash flow
11.92×
Free cash flow
$18.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RXST, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.59M
$33.74M
$30.89M
$32.61M
$30.34M
$33.64M
$37.9M
$40.21M
Cost of revenue
$6.49M
$7.86M
$7.4M
$7.35M
$6.11M
$8.45M
$9.57M
$11.43M
Gross profit
$18.1M
$25.89M
$23.5M
$25.26M
$24.23M
$25.19M
$28.33M
$28.79M
Selling, general and administrative
$27.4M
$30.42M
$31.86M
$27.7M
$27.35M
$28.98M
$28.64M
$28.21M
Research and development
$9.21M
$9.24M
$9.47M
$8.91M
$9.06M
$10.22M
$10.37M
$9.21M
Total operating expenses
$36.62M
$39.66M
$41.33M
$36.6M
$36.41M
$39.19M
$39M
$37.42M
Operating income
-$18.52M
-$13.77M
-$17.83M
-$11.34M
-$12.18M
-$14M
-$10.67M
-$8.63M
Interest expense
-$3K
-$3K
-$3K
-$5K
-$4K
-$5K
-$6K
-$5K
Income before taxes
-$16.2M
-$12.01M
-$15.88M
-$9.15M
-$9.81M
-$11.75M
-$8.17M
-$5.93M
Income taxes
$28K
$88K
$6K
$5K
$10K
$32K
$18K
$12K
Net income
-$16.22M
-$12.1M
-$15.88M
-$9.15M
-$9.82M
-$11.79M
-$8.19M
-$5.94M
Net income attributable to common shareholders
-$16.27M
-$12.1M
-$16M
-$9.15M
-$9.64M
-$11.79M
-$8.34M
-$5.94M
EBITDA
-$17.59M
-$12.77M
-$17M
-$10.49M
-$11.32M
-$13.22M
-$9.9M
-$8.11M
Basic earnings per share
-$0.39
-$0.29
-$0.38
-$0.22
-$0.24
-$0.29
-$0.20
-$0.15
Diluted earnings per share
-$0.39
-$0.29
-$0.38
-$0.22
-$0.24
-$0.29
-$0.20
-$0.15
Recent news
Company coverage with links to the original publishers.
RxSight (RXST) beat EPS expectations with a loss of $0.21 per share versus consensus estimate of $0.29, representing a 27.59% earnings surprise. However, the company missed revenue estimates, posting $24.59 million versus the expected amount, down from $30.34 million year-over-year. The stock has underperformed significantly, down 53.9% year-to-date. RxSight holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
K2 Vision, a Pacific Northwest and Arizona-based vision correction practice, has completed 5,000 Light Adjustable Lens (LAL) procedures and been recognized by RxSight as the world's highest-volume LAL practice. The LAL is the first lens implant that can be adjusted after placement through noninvasive light treatments, allowing for customized vision correction based on patient needs.
RxSight, Inc. announced preliminary 2025 full-year revenue of $134.5 million, exceeding guidance, driven by 109,615 Light Adjustable Lens procedures (12% increase YoY) and expansion of its installed base to 1,134 Light Delivery Devices. The company also appointed Mark Wilterding as Chief Financial Officer, bringing 25+ years of medtech financial leadership experience from Edwards Lifesciences.
DJS Law Group is investigating RxSight, Inc. for potential securities law violations after the company reported significant financial declines, including reduced sales of Light Delivery Devices and lowered annual financial guidance.
Faruqi & Faruqi is investigating potential securities law violations by RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.